PTGX
Protagonist Therapeutics, Inc.
19.97
USD
This page is just a preview of the data found in TrendSpider’s full version
Protagonist Therapeutics, Inc. stock is up 28.92% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 11 Dec 17:05 | 19 Jan, 2024 | 20.00 | 9 |
Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.
